Drugs / Capecitabine
Capecitabine
English name capecitabine
also known as
Xeloda · CAP · Capecitabine(Xeloda) · CAPE · Xeloda (Capecitabine) · Capecitabine tablets · 5-FU · Capecitabina · +21 more
Small molecule targets TYMS
Regulatory milestones approvals, filings & regulatory actions · 8 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (6) | US (FDA) | XELODA | — | 2001-04-30 – 2022-12-14 | fda.gov ↗ |
| Approved | EU (EMA) | Xeloda | — | 2001-02-02 | europa.eu ↗ |
| Approved | US (FDA) | XELODA | — | 1998-04-30 | fda.gov ↗ |
Trials 1,521 · started per year
today
US approved 1998
EU approved 2001
3
6
11
16
40
53
73
63
74
53
53
60
52
46
41
48
38
42
47
45
61
48
67
58
72
87
107
76
77
1998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT06406816 | May 2024 → May 2026 overdue | intrahepatic cholangiocarcinoma | Yongyi Zeng | Recruiting | No outcome recorded |
| Phase 0 | NCT05238831 | Jan 2023 → May 2026 | female breast carcinoma, ovarian carcinoma, pancreatic ductal adenocarcinoma, pancreatic large cell neuroendocrine carcinoma +2 | OHSU Knight Cancer Institute | Withdrawn | No outcome recorded |
| Phase 0 | NCT03515941 | Jun 2018 → Mar 2020 | digestive system cancer | Tannaz Armaghany | Terminated | No outcome recorded |
| Phase 0 | NCT01821612 | May 2013 → Nov 2014 | pancreatic acinar cell carcinoma, pancreatic ductal adenocarcinoma | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 1169 trials · 2 met primary | ||||||
| Phase 1 | NCT07824934 | Sep 2026 → May 2028 expected | cancer | Sunshine Lake Pharma Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07453875 | May 2026 → Nov 2027 expected | peritoneal carcinomatosis | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07477743 | Mar 2026 → Dec 2027 expected | — | HC Biopharma Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05296005 | Dec 2025 | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Ohio State University Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT06848465 | Feb 2025 → Aug 2026 overdue | metastasis from malignant tumor of colon | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Recruiting | No outcome recorded |
| Phase 1 | NCT06621563 | Dec 2024 → Mar 2026 overdue | colorectal cancer, non-small cell lung carcinoma | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 1 | NCT06065371 | Nov 2024 → Dec 2026 expected | digestive system cancer | Henry Ford Health System | Recruiting | No outcome recorded |
| Phase 1 | NCT06544655 | Oct 2024 → Oct 2027 expected | cancer | Bristol-Myers Squibb | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06825624 | Oct 2024 → Oct 2026 expected | colorectal cancer | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 1 | NCT06346808 | May 2024 → May 2026 overdue | malignant pancreatic neoplasm | Sichuan University | Not yet recruiting | No outcome recorded |
| Show all 169 trials opens the full record — a long page | ||||||
| Phase 1/2143 trials · 5 met primary · 1 missed | ||||||
| Phase 1/2 | NCT07791758 | Sep 2026 → Sep 2030 expected | colorectal carcinoma | Nanjing Leads Biolabs Co.,Ltd | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07653685 | Sep 2026 → Jun 2027 expected | colorectal cancer | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07805551 | Aug 2026 → Aug 2030 expected | colorectal cancer | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07681297 | Aug 2026 → Aug 2028 expected | central nervous system disorder, triple-negative breast carcinoma | National University Hospital, Singapore | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07494448 | Jul 2026 → Dec 2027 expected | HER2 positive breast carcinoma | MedSIR | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07683949 | Jun 2026 → Oct 2029 expected | colorectal cancer | Seoul National University Bundang Hospital | Enrolling by invitation | No outcome recorded |
| Phase 1/2 | NCT07327229 | Feb 2026 → Sep 2027 expected | gastroesophageal adenocarcinoma | Antengene Biologics Limited | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07140393 | Oct 2025 → Oct 2027 expected | neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07161791 | Sep 2025 → Dec 2026 expected | triple-negative breast carcinoma | Harbin Medical University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06942234 | Jun 2025 → Jun 2027 expected | Her2-receptor negative breast cancer | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Recruiting | No outcome recorded |
| Show all 143 trials opens the full record — a long page | ||||||
| Phase 2865 trials · 26 met primary · 29 missed | ||||||
| Phase 2 | NCT07841873 | Nov 2026 → Jun 2028 expected | biliary tract cancer | Anhui Provincial Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07797244 | Oct 2026 → Apr 2029 expected | colorectal cancer | Dai, Guanghai | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07779694 | Oct 2026 → Dec 2028 expected | rectal carcinoma | Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07802418 | Oct 2026 → Jun 2031 expected | malignant pancreatic neoplasm | Herlev Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07802288 | Sep 2026 → Apr 2029 expected | gastroesophageal adenocarcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07815288 | Sep 2026 → Dec 2029 expected | colorectal adenocarcinoma | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07828756 | Sep 2026 → Oct 2027 expected | malignant pancreatic neoplasm | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07847710 | Sep 2026 → Mar 2028 expected | intrahepatic cholangiocarcinoma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT07800000 | Sep 2026 → Sep 2028 expected | anal canal squamous cell carcinoma | Wang Xin | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07833241 | Sep 2026 → Sep 2028 expected | pancreatic exocrine neoplasm | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Show all 865 trials opens the full record — a long page | ||||||
| Phase 2/350 trials · 3 met primary · 6 missed | ||||||
| Phase 2/3 | NCT07866313 | Jun 2026 → Aug 2028 expected | colorectal cancer | Changhai Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07490262 | Mar 2026 → Dec 2027 expected | hepatocellular carcinoma | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07392866 | Mar 2026 → Mar 2030 expected | hepatocellular carcinoma | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07251062 | Dec 2025 → Dec 2029 expected | esophageal squamous cell carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07309419 | Dec 2025 → Jun 2030 expected | hepatocellular carcinoma | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06841679 | Aug 2025 → Sep 2030 expected | gastroesophageal adenocarcinoma | Beijing Biostar Pharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06758830 | Jan 2025 → Dec 2029 expected | rectal cancer | National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06268327 | Apr 2024 → Oct 2025 overdue | breast cancer | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05976568 | Sep 2023 → Sep 2027 expected | hepatocellular carcinoma | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05902533 | Aug 2023 → Aug 2026 overdue | anal carcinoma | University of Cincinnati | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05980481 | Aug 2023 → Jul 2025 overdue | gastric cancer | RemeGen Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05462613 | May 2023 → Nov 2029 expected | colorectal cancer | Centre Hospitalier Universitaire de Besancon | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05610163 | Dec 2022 → Jul 2030 expected | rectum adenocarcinoma | Alliance for Clinical Trials in Oncology | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05288777 | Jul 2022 → Dec 2028 expected | breast cancer | University of Virginia | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05065957 | Mar 2022 → Jul 2026 overdue | biliary tract cancer | InnoPharmax Inc. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04749108 | Nov 2021 → Sep 2029 expected | rectal carcinoma | Institut du Cancer de Montpellier - Val d'Aurelle | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04803539 | Apr 2021 → Sep 2028 expected | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03959150 | Jan 2020 → Jun 2022 | malignant pancreatic neoplasm | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT04068103 | Dec 2019 → Jun 2023 overdue | colon adenocarcinoma | NRG Oncology | Active not recruiting | Missed primary |
| Phase 2/3 | NCT03512756 | Mar 2018 → Dec 2021 | malignant pancreatic neoplasm | Tyme, Inc | Terminated | No outcome recorded |
| Phase 2/3 | NCT03423849 | Feb 2018 → Feb 2020 | breast cancer | Zhiyong Yu | Unknown | No outcome recorded |
| Phase 2/3 | NCT03158610 | Jan 2018 → Apr 2021 | colorectal cancer | Ruijin Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT03507465 | Nov 2017 → Nov 2019 | breast cancer | Guangdong Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT03957733 | Nov 2017 → May 2022 | rectal cancer | King Abdullah Medical City | Unknown | No outcome recorded |
| Phase 2/3 | NCT02945566 | Jun 2017 → Aug 2027 expected | rectum adenocarcinoma | University of Birmingham | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT02758951 | Jun 2017 → Oct 2024 overdue | colorectal adenocarcinoma, peritoneal carcinoma, peritoneal carcinomatosis | Koen Rovers | Active not recruiting | Missed primary |
| Phase 2/3 | NCT02741856 | Nov 2016 → Apr 2021 | esophageal cancer | Lisette Nixon | Unknown | Missed primary |
| Phase 2/3 | NCT02777437 | Oct 2016 → Oct 2019 | colonic neoplasm | Fudan University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02893540 | Sep 2016 → Dec 2018 | colorectal cancer | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT02529774 | Sep 2015 → Sep 2020 | metastasis from malignant tumor of colon | Ye Xu | Unknown | No outcome recorded |
| Phase 2/3 | NCT02311439 | Oct 2014 → Nov 2016 | malignant pancreatic neoplasm | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT01787539 | Feb 2013 → Feb 2017 | gastric cancer | Medical University of Lublin | Unknown | No outcome recorded |
| Phase 2/3 | NCT01515787 | Jun 2012 → Dec 2022 | colorectal cancer | Alliance for Clinical Trials in Oncology | Unknown | Met primary |
| Phase 2/3 | NCT01662128 | Jun 2012 → Jun 2014 | breast cancer | Tianjin Medical University | Unknown | No outcome recorded |
| Phase 2/3 | NCT01516944 | Feb 2012 → Apr 2018 | gastric cancer | Hebei Medical University | Completed | Met primary |
| Phase 2/3 | NCT03428529 | Jan 2011 → Oct 2016 | rectal cancer | Brazilian National Cancer Institute | Completed | No outcome recorded |
| Phase 2/3 | NCT01097265 | Jul 2010 → Jan 2015 | colorectal cancer | Jeroen Bosch Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT01064999 | Mar 2010 → Mar 2012 | rectal cancer | Fudan University | Unknown | Missed primary |
| Phase 2/3 | NCT01415336 | Mar 2010 → Mar 2013 | breast cancer | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT01065870 | Dec 2009 → Dec 2014 | pancreas disorder | Columbia University | Unknown | No outcome recorded |
| Phase 2/3 | NCT01924819 | Sep 2009 → Dec 2026 expected | gastric cancer | Australasian Gastro-Intestinal Trials Group | Active not recruiting | Missed primary |
| Phase 2/3 | NCT01204437 | Mar 2009 → Jan 2014 | breast cancer | GBG Forschungs GmbH | Completed | No outcome recorded |
| Phase 2/3 | NCT00647530 | May 2008 → Dec 2016 | colorectal cancer | University of Birmingham | Unknown | Met primary |
| Phase 2/3 | NCT00561522 | Nov 2007 → Jul 2012 | hepatocellular carcinoma, metastatic neoplasm | Fudan University | Unknown | No outcome recorded |
| Phase 2/3 | NCT00397761 | Jul 2006 → ? | breast cancer | Medstar Health Research Institute | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT00418028 | Sep 2005 → Dec 2011 | breast cancer | Hospital San Carlos, Madrid | Completed | Missed primary |
| Phase 2/3 | NCT00294359 | Jun 2005 → Jul 2007 | colorectal cancer | Australasian Gastro-Intestinal Trials Group | Completed | No outcome recorded |
| Phase 2/3 | NCT01196260 | Jan 2004 → Dec 2020 | colorectal cancer | State Key Laboratory of Cancer Biology | Unknown | No outcome recorded |
| Phase 2/3 | NCT00960284 | Jun 2003 → Jun 2009 | pancreatic adenocarcinoma | IRCCS San Raffaele | Completed | No outcome recorded |
| Phase 2/3 | NCT00049660 | Sep 2002 → Dec 2004 | female breast carcinoma | European Organisation for Research and Treatment of Cancer - EORTC | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3207 trials · 28 met primary · 24 missed | ||||||
| Phase 3 | NCT07591493 | Sep 2026 → Jun 2035 expected | pancreatic neuroendocrine tumor | Gustave Roussy, Cancer Campus, Grand Paris | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07584135 | May 2026 → Jan 2029 expected | gastric adenocarcinoma | NingBo Junyan Hongshi Biosciences Co., Ltd | Recruiting | No outcome recorded |
| Phase 3 | NCT07590024 | May 2026 → Dec 2030 expected | nasopharyngeal carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 3 | NCT07340567 | May 2026 → Nov 2032 expected | colorectal cancer | UNICANCER | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06346197 | Dec 2025 → May 2028 expected | gastric cancer, metastatic malignant neoplasm | Centre Leon Berard | Recruiting | No outcome recorded |
| Phase 3 | NCT07238569 | Dec 2025 → Dec 2029 expected | nasopharyngeal carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07467330 | Nov 2025 → Dec 2031 expected | breast cancer | Fujian Cancer Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT07154069 | Nov 2025 → Sep 2031 expected | nasopharyngeal carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT07188025 | Oct 2025 → Oct 2030 expected | rectal cancer | Erasmus Medical Center | Recruiting | No outcome recorded |
| Phase 3 | NCT07248670 | Oct 2025 → Dec 2031 expected | nasopharyngeal carcinoma | Chongqing University Cancer Hospital | Active not recruiting | No outcome recorded |
| Show all 207 trials opens the full record — a long page | ||||||
| Phase 428 trials | ||||||
| Phase 4 | NCT07801027 | Nov 2026 → Jan 2030 expected | biliary tract cancer, gastric neoplasm, gastroesophageal junction adenocarcinoma, uterine cervix neoplasm | Merck Sharp & Dohme LLC | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07483060 | Mar 2026 → Dec 2028 expected | rectal cancer | Vastra Gotaland Region | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07158164 | Aug 2025 → Jul 2027 expected | breast neoplasm, colorectal neoplasm, head and neck neoplasm, intraepithelial neoplasia | Rutgers, The State University of New Jersey | Recruiting | No outcome recorded |
| Phase 4 | NCT06931808 | Mar 2025 → Mar 2026 overdue | rectum adenocarcinoma | First Affiliated Hospital of Ningbo University | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT06550453 | Sep 2024 → Jan 2025 overdue | colorectal carcinoma | yangjianjun | Recruiting | No outcome recorded |
| Phase 4 | NCT05203172 | Jul 2022 → Jul 2029 expected | cancer | Pfizer | Recruiting | No outcome recorded |
| Phase 4 | NCT04747951 | Oct 2020 → Oct 2023 | rectal cancer | State Scientific Centre of Coloproctology, Russian Federation | Unknown | No outcome recorded |
| Phase 4 | NCT04480268 | Jul 2020 → Jan 2022 | pancreatic ductal adenocarcinoma | IRCCS San Raffaele | Unknown | No outcome recorded |
| Phase 4 | NCT04767828 | May 2020 → Jun 2022 | thrombotic thrombocytopenic purpura | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04031885 | Aug 2019 → Aug 2020 | breast cancer | Eli Lilly and Company | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03355157 | Mar 2018 → Aug 2024 | breast cancer | GBG Forschungs GmbH | Completed | No outcome recorded |
| Phase 4 | NCT03465202 | May 2016 → May 2018 | breast cancer, colorectal cancer | Newcastle-upon-Tyne Hospitals NHS Trust | Unknown | No outcome recorded |
| Phase 4 | NCT02575378 | Sep 2015 → Jun 2018 | colorectal cancer | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02248571 | Aug 2014 → Aug 2017 | female breast carcinoma, hormone receptor-positive breast cancer | iOMEDICO AG | Completed | No outcome recorded |
| Phase 4 | NCT02380131 | Feb 2013 → Dec 2017 | gastroesophageal adenocarcinoma | Hebei Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT00854477 | Nov 2009 → Aug 2012 | pancreatic adenocarcinoma | Cambridge University Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| Phase 4 | NCT00871273 | Nov 2009 → Oct 2013 | gastric adenocarcinoma | Cambridge University Hospitals NHS Foundation Trust | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00812864 | Jan 2009 → Oct 2011 | breast cancer, colorectal cancer | University Hospital, Limoges | Completed | No outcome recorded |
| Phase 4 | NCT00577031 | Feb 2008 → Aug 2011 | colorectal cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT00502671 | Jul 2007 → Mar 2012 | colorectal cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT02581423 | Aug 2005 → Mar 2007 | colorectal cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT00127933 | Aug 2005 → Apr 2009 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT00121836 | Jun 2005 → Dec 2008 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT00559676 | Mar 2005 → May 2011 | colorectal cancer | Centre Hospital Regional Universitaire de Limoges | Completed | No outcome recorded |
| Phase 4 | NCT00216424 | Feb 2005 → Jan 2007 | colorectal cancer | James A. Haley Veterans Administration Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02567331 | Oct 2004 → Apr 2006 | colorectal cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT00087620 | Sep → Oct 2004 | breast cancer | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 4 | NCT00220168 | Jan 2003 → ? | gastroesophageal cancer | Royal Marsden NHS Foundation Trust | Completed | No outcome recorded |
| Phase not applicable53 trials · 1 missed | ||||||
| — | NCT07854964 | Oct 2026 → May 2030 expected | — | Tang-Du Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07859410 | Oct 2026 → Oct 2028 expected | gastroesophageal junction adenocarcinoma | Anhui Medical University | Not yet recruiting | No outcome recorded |
| — | NCT07563907 | Jun 2026 → Dec 2030 expected | rectal carcinoma | Seoul National University Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07474103 | Nov 2025 → Mar 2028 expected | rectum adenocarcinoma | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| — | NCT07334587 | Sep 2025 → Feb 2026 overdue | colorectal carcinoma | Allama Iqbal Medical College | Enrolling by invitation | No outcome recorded |
| — | NCT06434493 | Nov 2024 → Jun 2028 expected | cholangiocarcinoma | The Christie NHS Foundation Trust | Not yet recruiting | No outcome recorded |
| — | NCT06578052 | Aug 2024 → Sep 2027 expected | malignant pancreatic neoplasm | Junjie Hang | Recruiting | No outcome recorded |
| — | NCT06463548 | Jul 2024 → Dec 2025 overdue | biliary tract cancer | Yunpeng Liu | Not yet recruiting | No outcome recorded |
| — | NCT06052332 | Feb 2024 → Dec 2029 expected | — | Jules Bordet Institute | Recruiting | No outcome recorded |
| — | NCT06115733 | Dec 2023 → Dec 2026 expected | colorectal carcinoma | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
| — | NCT06156761 | Nov 2023 → Apr 2024 | breast cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| — | NCT06158919 | Nov 2023 → Nov 2024 overdue | gastroesophageal junction adenocarcinoma | Fudan University | Recruiting | No outcome recorded |
| — | NCT06035133 | Nov 2023 → Nov 2024 overdue | rectal cancer | Tang-Du Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06157216 | Oct 2023 → Apr 2027 expected | gastric cancer | Qilu Hospital of Shandong University | Active not recruiting | No outcome recorded |
| — | NCT05877573 | Jul 2023 → Jan 2025 overdue | rectal cancer | Nanfang Hospital, Southern Medical University | Recruiting | No outcome recorded |
| — | NCT05876065 | Jun 2023 → Jun 2026 overdue | breast cancer | Wenjin Yin | Recruiting | No outcome recorded |
| — | NCT05494190 | Nov 2022 → Nov 2027 expected | hypopharyngeal carcinoma | Eye & ENT Hospital of Fudan University | Recruiting | No outcome recorded |
| — | NCT06048146 | Oct 2022 → Sep 2025 | metastatic malignant neoplasm in the lymph nodes, rectal cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Completed | No outcome recorded |
| — | NCT05496491 | Aug 2022 → Aug 2026 overdue | rectal cancer | Larissa University Hospital | Recruiting | No outcome recorded |
| — | NCT06246461 | Jan 2022 → Dec 2023 | — | Jingjiang People's Hospital | Completed | No outcome recorded |
| — | NCT04891900 | May 2021 → Dec 2024 | gastric cancer, gastroesophageal junction adenocarcinoma | Henan Cancer Hospital | Unknown | No outcome recorded |
| — | NCT06015100 | Feb 2021 → Aug 2023 | breast cancer | Yan Xue | Unknown | No outcome recorded |
| — | NCT04894643 | Sep 2020 → Dec 2026 expected | malignant pancreatic neoplasm | EBG MedAustron GmbH | Recruiting | No outcome recorded |
| — | NCT03904043 | Jul 2020 → Aug 2024 | rectum adenocarcinoma | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT04194957 | Jan 2020 → Jan 2021 | neoplasm | The Netherlands Cancer Institute | Unknown | No outcome recorded |
| — | NCT04198051 | Dec 2019 → Dec 2020 | colon carcinoma, gastric cancer | The First Affiliated Hospital of Dalian Medical University | Unknown | No outcome recorded |
| — | NCT03821454 | Feb 2019 → Feb 2020 | breast cancer | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| — | NCT03647514 | Dec 2018 → Sep 2020 | breast cancer | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| — | NCT03398512 | Feb 2018 → Mar 2020 | peritoneal carcinomatosis | Wuhan University | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT03071198 | Mar 2017 → Sep 2018 | rectal cancer | Harbin Medical University | Unknown | No outcome recorded |
| — | NCT03042000 | Feb 2017 → Dec 2020 | rectum adenocarcinoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| — | NCT02324452 | Mar 2015 → Jan 2018 | neoplasm | The Netherlands Cancer Institute | Completed | No outcome recorded |
| — | NCT02358863 | Feb 2015 → Nov 2016 | esophageal cancer, gastric cancer | Georgetown University | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT02028494 | Aug 2013 → Dec 2018 | breast cancer | Latin American & Caribbean Society of Medical Oncology | Unknown | No outcome recorded |
| — | NCT01828554 | Jun 2013 → Apr 2018 | neoplasm, obesity disorder | University of Wisconsin, Madison | Completed | No outcome recorded |
| — | NCT01792934 | May 2013 → Jan 2025 overdue | colorectal cancer | Radboud University Medical Center | Active not recruiting | Missed primary |
| — | NCT01549795 | Jan 2012 → Jul 2013 | hilar cholangiocarcinoma, primary sclerosing cholangitis | Azienda Ospedaliera di Padova | Unknown | No outcome recorded |
| — | NCT01295086 | Mar 2011 → Nov 2014 | adenocarcinoma | Odense University Hospital | Completed | No outcome recorded |
| — | NCT01369433 | Jun 2010 → Jun 2015 | cancer | AVEO Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| — | NCT01280643 | Mar 2010 → Jul 2013 | colorectal cancer | Fox Chase Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01366118 | Oct 2009 → Apr 2011 | rectal carcinoma | Grupo Hospital de Madrid | Completed | No outcome recorded |
| — | NCT00953537 | Jan 2009 → Jan 2011 | breast cancer | Centre Antoine Lacassagne | Completed | No outcome recorded |
| — | NCT00535041 | Sep 2007 → Sep 2015 | rectal neoplasm | King Faisal Specialist Hospital & Research Center | Completed | No outcome recorded |
| — | NCT00524069 | Jan → Nov 2007 | pancreatic adenocarcinoma | Roswell Park Cancer Institute | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT00430027 | Nov 2006 → Aug 2008 | esophageal adenocarcinoma | University of Colorado, Denver | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00577057 | Sep 2006 → Aug 2013 | nasopharyngeal neoplasm | Hospital Authority, Hong Kong | Unknown | No outcome recorded |
| — | NCT00121134 | Jun 2005 → May 2009 | breast cancer | Harold J. Burstein, MD, PhD | Completed | No outcome recorded |
| — | NCT00159471 | Feb 2005 → Jun 2006 | malignant pancreatic neoplasm | University of Southern California | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00250029 | Apr 2004 → Sep 2005 | cancer, colonic disorder | New Mexico Cancer Research Alliance | Completed | No outcome recorded |
| — | NCT00156312 | Jul 2003 → May 2005 | breast cancer | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| — | NCT00146588 | Apr 2002 → Dec 2004 | breast cancer | Craig A. Bunnell, MD, MPH | Completed | No outcome recorded |
| — | NCT00176735 | Dec 2001 → Aug 2005 | malignant pancreatic neoplasm | University of Michigan Rogel Cancer Center | Terminated | No outcome recorded |
| — | NCT02043821 | ? → Jan 2016 | colorectal cancer | Beijing Chao Yang Hospital | Unknown | No outcome recorded |
| Phase not stated2 trials | ||||||
| — | NCT00338247 | Jul 2006 → Mar 2015 | breast cancer | Novartis | Approved for marketing | No outcome recorded |
| — | NCT04220203 | — | HER2 positive breast carcinoma | Pfizer | Approved for marketing | No outcome recorded |
| Comparator or background therapy852 trials | ||||||
| Phase 0 | NCT07328087 Background | Feb 2026 → Dec 2030 expected | colorectal cancer | Biogenea Pharmaceuticals Ltd. | Recruiting | No outcome recorded |
| Phase 0 | NCT05108428 Background | Dec 2021 → Oct 2023 overdue | rectum adenocarcinoma | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07652242 Background | Jul 2026 → Feb 2028 expected | triple-negative breast carcinoma | Immunomic Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT07024615 Background | Oct 2025 → Jan 2028 expected | pancreatic ductal adenocarcinoma | Astellas Pharma Global Development, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT07114601 Background | Aug 2025 → Apr 2030 expected | breast neoplasm, colorectal neoplasm, endometrium neoplasm, gastric neoplasm +3 | Eli Lilly and Company | Recruiting | No outcome recorded |
| Show all 852 trials opens the full record — a long page | ||||||
Press releases naming this drug 23 releases
Evidence & citations 34 cited values
Every value below carries the sentence it was read from. 2,383 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Capecitabine | “RCT Cap 50 will combine radiotherapy at a dose of 50 Gy by either conventional 3D or Intensity-Modulated RadioTherapy (IMRT) (2 Gy per fraction, 5 fractions per week during 5...” NCT04749108 ↗2345“Patients (pts) with HER2-positive (gene amplification or increased copy numbers based on predefined criteria) advanced GC were randomly allocated 1:1 to receive LAP 1250mg per...” PMID 25694417 ↗ Feb 2015 “RCT Cap 50 will combine radiotherapy at a dose of 50 Gy by either conventional 3D or IMRT (2 Gy per fraction, 5 fractions per week during 5 weeks / 44 Gy in mini pelvis, and...” NCT01333709 ↗ “After achieving an objective response (ORR) with the combination of MRG003 and Tislelizumab, maintenance therapy will consist of Capecitabine (650 mg/m², administered twice...” NCT07331428 ↗ “The dosing regimen during the dose escalation phase will include three different doses of fruquintinib (3 mg, 4 mg and 5 mg, per oral, once per day days 1-14) + sintilimab,...” PMID 41005780 ↗ Sep 2025 “After achieving objective tumor response or stable disease after 3 cycles of capecitabine and oxaliplatin or 4 cycles of 5-fluorouracil and oxaliplatin with or without...” PMID 41837962 ↗ Apr 2026 “Any of the following single-agent chemotherapy may be given at the discretion of the investigator, with a cycle length not to exceed four weeks: Capecitabine, Vinorelbine,...” NCT01156753 ↗ “Participants will receive 6 cycles of a standard intravenous or oral chemotherapy regimen or an Antibody-Drug Conjugate (ADC), selected by the investigator from...” NCT07371910 ↗ “The neoadjuvant treatment regimen will consist of Oxaliplatin at a dose of 130mg/m2, administered intravenously over a period of more than 2 hours on Day 1, every 3 weeks; and...” NCT06014372 ↗ “The main objective of the SIRTCI study is to evaluate the safety and efficacy of the combination chemotherapy (XELOX: Capecitabine plus oxaliplatin), anti-angiogenic...” NCT04659382 ↗ “CRT (1 cycle CT: Xelox or SOX, Q21d×1, Followed by RT: 45 Gray (Gy), 5d/week×5 with capecitabine or S1, Followed by 3 cycles CT: Xelox or SOX, Q21d×3) will be applied to...” NCT03680261 ↗ |
| Known as | 5-FU | “5-FU (Capecitabine) Consolidation chemotherapy 3 cycles” NCT07563907 ↗ |
| Known as | CAP | “Patients (pts) with HER2-positive (gene amplification or increased copy numbers based on predefined criteria) advanced GC were randomly allocated 1:1 to receive LAP 1250mg per...” PMID 25694417 ↗ Feb 201510“To evaluate the clinical efficacy of adding temozolomide (TMZ) to preoperative capecitabine (CAP)-based chemoradiotherapy in patients with locally advanced rectal cancer (LARC)...” PMID 36376167 ↗ Nov 2022 “AIM OF THE STUDY: Evaluation of the impact of a de-escaleted chemotherapy regimen consisting of capecitabine (Cap) on invasive disease-free survival (iDFS) in patients ≥65...” PMID 37797387 ↗ Sep 2023 “PURPOSE: We performed a UGT1A1 genotype-guided study to determine the maximum tolerated dose (MTD) and evaluate the toxicities and pharmacokinetics of the combination of...” PMID 24114122 ↗ Oct 2013 “A Pivotal Phase II Clinical Trial of Utidelone Injection (UTD1) Plus Capecitabine (CAP) in HER2-negative Breast Cancer Patients With Brain Metastases” NCT06764940 ↗ “This is an open label study to assess the efficacy of capecitabine (CAP) and temozolomide (TMZ) in recurrent pituitary adenomas.” NCT03930771 ↗ “capecitabine (CAP) in patients with previously treated unresectable, locally advanced or metastatic breast cancer.” PMID 28220020 ↗ Feb 2017 “bevacizumab (BEV) to preoperative capecitabine (CAP)-based CRT in LARC” PMID 25886378 ↗ Feb 2015 “All pts were treated with Capecitabine (Cap) 625-825 mg/m2/12h M-F.” NCT01366118 ↗ “gemcitabine (Gem) plus capecitabine (Cap) versus single-agent Gem” PMID 18669454 ↗ Aug 2008 “capecitabine (CAP)” PMID 37402471 ↗ Jul 2023 |
| Known as | CAPE | “Patients receive docetaxel as in Arm 1A and oral capecitabine (cape) twice daily on days 1-14 every 3 weeks for up to 4 cycles.” NCT00408408 ↗3“We investigate the replacement of 5-FU by the oral pro-drug capecitabine (cape) within a randomized phase III trial.” NCT01500993 ↗ “De-escalation treatment (capecitabine [CAPE] for 6 months).” NCT07340567 ↗ “Capecitabine (CAPE) or Xeloda® (XEL) + oxaliplatin (OX)” NCT00551213 ↗ |
| Known as | Capecitabina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1773 ↗ |
| Known as | Capecitabine (Cap) | “Capecitabine (Cap)” NCT03262935 ↗ |
| Known as | Capecitabine (XELODA ，Roche) | “Capecitabine (XELODA ，Roche)” NCT02027363 ↗ |
| Known as | Capecitabine (Xeloda○R), company: Roche | “Capecitabine (Xeloda○R), company: Roche” NCT01558011 ↗ |
| Known as | Capecitabine accord | ChEMBL registry synonym — accepted as the source's own label CHEMBL1773 ↗ |
| Known as | Capecitabine component of xeliri capecitibine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1773 ↗ |
| Known as | Capecitabine component of xelox | ChEMBL registry synonym — accepted as the source's own label CHEMBL1773 ↗ |
| Known as | Capecitabine medac | ChEMBL registry synonym — accepted as the source's own label CHEMBL1773 ↗ |
| Known as | Capecitabine sun | ChEMBL registry synonym — accepted as the source's own label CHEMBL1773 ↗ |
| Known as | Capecitabine tablets | “Drug: Capecitabine tablets” NCT05901935 ↗1“Drug: Capecitabine Tablets” NCT07606599 ↗ |
| Known as | Capecitabine teva | ChEMBL registry synonym — accepted as the source's own label CHEMBL1773 ↗ |
| Known as | Capecitabine(Xeloda) | “capecitabine (Xeloda®)” NCT01067053 ↗8“Capecitabine(Xeloda®)” NCT00853684 ↗ “Capecitabine (Xeloda)” NCT01195298 ↗ “Capecitabine (Xeloda)” NCT01640665 ↗ “Capecitabine (Xeloda)” NCT01196455 ↗ “Capecitabine (Xeloda)” NCT01941771 ↗ “Capecitabine: Xeloda” NCT01642771 ↗ “Capecitabine, Xeloda” NCT00961571 ↗ “Capecitabine: Xeloda” NCT01802970 ↗ |
| Known as | Capecitibine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1773 ↗ |
| Known as | Capecytabine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1773 ↗ |
| Known as | Capiibine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1773 ↗ |
| Known as | Captabin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1773 ↗ |
| Known as | Ecansya | ChEMBL registry synonym — accepted as the source's own label CHEMBL1773 ↗ |
| Known as | Ecansya (previously capecitabine krka) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1773 ↗ |
| Known as | metroCap | “RIBBON-LA-01 is a single-arm, open-label, phase 2 clinical trial of maintenance tislelizumab and metronomic capecitabine (metroCap) for 52 weeks after IC and CCRT” NCT06093061 ↗ |
| Known as | NSC-759853 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1773 ↗ |
| Known as | RO 09-1978/000 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1773 ↗ |
| Known as | XEL | “Capecitabine (CAPE) or Xeloda® (XEL) + oxaliplatin (OX)” NCT00551213 ↗ |
| Known as | Xeloda | “The hypothesis of this phase II trial is that the unique mechanisms of action and non-overlapping toxicity profiles of capecitabine (Xeloda) and erlotinib will allow these...” NCT00459901 ↗145“This is a prospective open label single-arm, single-institution phase II clinical trial to test the efficacy of neoadjuvant treatment with IXO (Irinotecan, Capecitabine...” NCT01237665 ↗ “For every five patients randomized, two will receive treatment number 1 (irofulven + prednisone), two patients will receive treatment number 2 (irofulven + capecitabine...” NCT00124566 ↗ “Neoadjuvant Epirubicin, Cisplatin and Capecitabine (Xeloda) [ECX] Followed by Definitive Chemoradiation With or Without Surgery for Patients With Newly Diagnosed Localized...” NCT00220129 ↗ “This study will evaluate the efficacy and safety of capecitabine (Xeloda) in combination with peginterferon alfa-2a (Pegasys) in participants with advanced liver cancer who...” NCT02576964 ↗ “A Phase 2 Study of the Efficacy and Safety of Irinotecan (Campto®) in Combination With Capecitabine (Xeloda®) as First-Line Chemotherapy in Asian Subjects With Inoperable...” NCT00635323 ↗ “Combination of the drug Taxotere together with a compound called 5-FU either as continuous infusion or in its oral form of a pill called "Xeloda" enhanced its anti cancer...” NCT00256841 ↗ “A Phase I/II, Multicentre Clinical Study Of ZD1839 (Iressa™) In Combination With Capecitabine (Xeloda™) In Subjects With Advanced Colorectal Carcinoma After Failure Of...” NCT00242788 ↗ “The purpose of this study is to investigate whether cetuximab (Erbitux®) with cisplatin and capecitabine (Xeloda) as 1st line treatment in the advanced gastric cancer is effective.” NCT00477711 ↗ “A Phase II Trial Of Celecoxib (Celebrex) And Capecitabine (Xeloda) Combined With Pelvic Irradiation As Neoadjuvant Treatment Of Stage II or III Adenocarcinoma Of The Rectum” NCT00081224 ↗ “Phase II Study of Trastuzumab (Herceptin) and Capecitabine (Xeloda) in Women With Taxanes and Anthracyclines Refractory Metastatic Breast Cancer and HER2 Over-Expression” NCT00107393 ↗ |
| Known as | Xeloda (Capecitabine) | “Xeloda (Capecitabine)” NCT00845884 ↗ |
| Known as | Xeloda Roche | “Oral Fluoropyrimidine Capecitabine (Xeloda Roche) Combined With Intravenous Cisplatin” NCT00010023 ↗ |
| Known as | Xelodaâ | “Phase II Study of the A-ICOX Regimen Consisting of Bevacizumab (Avastinâ), Intermittent Dose Capecitabine (Xelodaâ) and Oxaliplatin (Eloxatinâ) in Patients With Untreated...” NCT00177307 ↗ |
| Action | Inhibit | “Drugs used in chemotherapy, such as DJ-927 and capecitabine, use different ways to stop tumor cells from dividing so they stop growing or die.” NCT00077077 ↗ |
| Modality | Small molecule | “the oral fluoropyrimidine capecitabine” PMID 15197193 ↗ Jun 2004 |
| Route | Oral | “Patients receive oral capecitabine twice a day 7 days a week for 6 weeks” NCT00003704 ↗ |
| Target | TYMS | “The thymidylate synthase (TS) is an important target enzyme for antifolate drugs, such as 5-FU、UFT and capecitabine” NCT00816868 ↗ |